Adie Sam, Harris Ian A, Naylor Justine M, Mittal Rajat
All authors are from the Whitlam Orthopaedic Research Centre, Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia.
Can J Surg. 2017 Apr;60(2):86-93. doi: 10.1503/cjs.010616.
The dangers of using surrogate outcomes are well documented. They may have little or no association with their patient-important correlates, leading to the approval and use of interventions that lack efficacy. We sought to assess whether primary outcomes in surgical randomized controlled trials (RCTs) are more likely to be patient-important outcomes than surrogate or laboratory-based outcomes.
We reviewed RCTs assessing an operative intervention published in 2008 and 2009 and indexed in MEDLINE, EMBASE or the Cochrane Central Register of Controlled Trials. After a pilot of the selection criteria, 1 reviewer selected trials and another reviewer checked the selection. We extracted information on outcome characteristics (patient-important, surrogate, or laboratory-based outcome) and whether they were primary or secondary outcomes. We calculated odds ratios (OR) and pooled in random-effects meta-analysis to obtain an overall estimate of the association between patient importance and primary outcome specification.
In 350 included RCTs, a total of 8258 outcomes were reported (median 18 per trial. The mean proportion (per trial) of patient-important outcomes was 60%, and 66% of trials specified a patient-important primary outcome. The most commonly reported patient-important primary outcomes were morbid events (41%), intervention outcomes (11%), function (11%) and pain (9%). Surrogate and laboratory-based primary outcomes were reported in 33% and 8% of trials, respectively. Patient-important outcomes were not associated with primary outcome status (OR 0.82, 95% confidence interval 0.63-1.1, 2 = 21%).
A substantial proportion of surgical RCTs specify primary outcomes that are not patient-important. Authors, journals and trial funders should insist that patient-important outcomes are the focus of study.
使用替代结局的风险已有充分记录。它们可能与对患者重要的相关指标几乎没有关联,导致缺乏疗效的干预措施获得批准并得以使用。我们试图评估外科随机对照试验(RCT)中的主要结局是否比替代结局或基于实验室的结局更有可能是对患者重要的结局。
我们检索了2008年和2009年发表并被MEDLINE、EMBASE或Cochrane对照试验中央注册库收录的评估手术干预的RCT。在对纳入标准进行预试验后,一名审阅者选择试验,另一名审阅者检查所选试验。我们提取了有关结局特征(对患者重要的结局、替代结局或基于实验室的结局)以及它们是主要结局还是次要结局的信息。我们计算了比值比(OR),并采用随机效应荟萃分析进行汇总,以获得对患者重要性与主要结局设定之间关联的总体估计。
在纳入的350项RCT中,共报告了8258个结局(每项试验中位数为18个)。对患者重要的结局的平均比例(每项试验)为60%,66%的试验设定了对患者重要的主要结局。最常报告的对患者重要的主要结局是不良事件(41%)、干预结局(11%)、功能(11%)和疼痛(9%)。分别有33%和8%的试验报告了替代结局和基于实验室的主要结局。对患者重要的结局与主要结局状态无关(OR 0.82,95%置信区间0.63 - 1.1,I² = 21%)。
相当一部分外科RCT设定的主要结局并非对患者重要的结局。作者、期刊和试验资助者应坚持将对患者重要的结局作为研究重点。